Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 11/20 | 0.59 |
| ▸ | NPC1 | O15118 | 9/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29883001 | 1.00 | PTK2 (0.62) | PTK2RAB9ANPC1TSHRMEN1 | |
| Ammonia Solution, Strong SCHEMBL27883856 | 0.98 | PTK2 (0.61) | PTK2RAB9ANPC1TSHRMEN1 | |
| Dimethylamine SCHEMBL6611746 | 0.96 | PTK2 (0.59) | PTK2RAB9ANPC1TSHRMEN1 | |
| SCHEMBL28461146 | 0.90 | PTK2 (0.53) | PTK2RAB9ANPC1TSHRMEN1 | |
| SCHEMBL1067851 | 0.82 | TSHR (0.65) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL29251156 | 0.82 | TDP1 (0.67) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL5689000 | 0.81 | RAB9A (0.60) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL2147165 | 0.81 | RAB9A (0.49) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL16166784 | 0.81 | RAB9A (0.61) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL27897933 | 0.81 | RAB9A (0.74) | RAB9ANPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109761957-B | Hydroxyproline-containing compound and preparation method and application thereof | 西安交通大学 | 2020-05-19 | — | — | CN | claimed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | DRAIG THERAPEUTICS LTD (GB) | 2024-12-26 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| EP-4334301-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | University College Cardiff Consultants Limited (GB) | 2024-03-13 | — | — | EP | disclosed |
| CN-117279908-A | Heteroaryl compounds for the treatment of cognitive disorders | 加的夫大学学院咨询有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230086702-A1 | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-23 | — | — | US | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5453512-A | Bromination of acylaminopyridine with 2-acylaminopyridinium hydorbromide | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-09-26 | — | — | US | disclosed |
| US-5453512-A | Bromination of acylaminopyridine with 2-acylaminopyridinium hydorbromide | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-09-26 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| US-5290943-A | Halogenation of pyridine compound | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| US-5290943-A | Halogenation of pyridine compound | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0530524-A1 | Method of producing 2-amino-3-nitro-5-halogenopyridine | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
| EP-0530524-A1 | Method of producing 2-amino-3-nitro-5-halogenopyridine | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | PTK2 279/4885RAB9A 2341/4885NPC1 2478/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | PTK2 272/4885RAB9A 2340/4885NPC1 2404/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PTK2 272/4885RAB9A 2340/4885NPC1 2404/4885 |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | GABRA5, GABRB3, GABRA3 | PTK2 3766/4885RAB9A 740/4885NPC1 1335/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | PTK2 3223/4885RAB9A 893/4885NPC1 4533/4885 |
| US-20230086702-A1 | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND USE THEREOF | SNCA, PSEN2, PRNP | PTK2 1233/4885RAB9A 760/4885NPC1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.